Rotavirus Vaccination is a Protective Factor for Adverse Outcomes in Primary Intussusception: a Single-center Retrospective Study

Overview

Journal Transl Pediatr

Publisher AME Publishing Company

Specialty Pediatrics

Date 2024 Jul 10

PMID 38984032

Authors

Min Du

Lihong Shang

Xin Li

Rongna Huang

Haibo Yao

Sheng Yang

Sujing Zhao

Libing Zhang

Xiaoli Xie

Affiliations

Soon will be listed here.

Abstract

Background: The clinical features and prognosis of intussusception in children vaccinated against rotavirus were undefined. Hence, we conducted the study to explore the clinical characteristics and outcomes of primary intussusception patients who received rotavirus vaccine.

Methods: A single-center retrospective study was performed in 327 primary intussusception patients between January 2019 and December 2021. Of these, 168 were vaccinated against rotavirus and 159 were not, the latter serving as the control group. Data on patients' clinical characteristics, commonly used inflammatory biomarkers, treatment, and outcomes were collected and evaluated.

Results: Most of the vaccination group received pentavalent rotavirus vaccine produced by Merck, USA (89.88%). There were no differences in demographic characteristics, time from onset to hospital attendance, clinical symptoms and signs between the vaccination group and the control group. The success rate of air enema reduction in the vaccination group was higher than that in the control group (98.21% . 88.68%, q=0.01). The vaccination group had lower rates of surgery and complication (1.79% . 11.32%, q=0.008; 2.98% . 12.58%, q=0.006). Both platelet-lymphocyte ratio (PLR) and C-reactive protein (CRP) levels were lower in the vaccinated group (q=0.02, q=0.004). Higher CRP level [odds ratio (OR): 1.635; 95% confidence interval (CI): 1.248-2.143; P=0.006] and the longer time from onset to hospital attendance (OR: 3.040; 95% CI: 2.418-12.133; P=0.01) were associated with increased adverse events. Rotavirus vaccination (OR: 0.527; 95% CI: 0.103-0.751; P=0.02) was associated with a reduction in the probability of adverse events.

Conclusions: Adverse events such as surgery and complications were lower in the vaccination group. Rotavirus vaccination was an independent protective factor for adverse events in patients with primary intussusception.

References

Clark A, Hasso-Agopsowicz M, Kraus M, Stockdale L, Sanderson C, Parashar U . Update on the global epidemiology of intussusception: a systematic review of incidence rates, age distributions and case-fatality ratios among children aged <5 years, before the introduction of rotavirus vaccination. Int J Epidemiol. 2019; 48(4):1316-1326. PMC: 6693807. DOI: 10.1093/ije/dyz028. View

Escolano S, Hill C, Tubert-Bitter P . Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach. Vaccine. 2015; 33(8):1017-20. DOI: 10.1016/j.vaccine.2015.01.005. View

Reddy S, Nair N, Tate J, Thiyagarajan V, Giri S, Praharaj I . Intussusception after Rotavirus Vaccine Introduction in India. N Engl J Med. 2020; 383(20):1932-1940. PMC: 7492078. DOI: 10.1056/NEJMoa2002276. View

Wang G, Zhang K, Zhang R, Kong X, Guo C . Impact of vaccination with different types of rotavirus vaccines on the incidence of intussusception: a randomized controlled meta-analysis. Front Pediatr. 2023; 11:1239423. PMC: 10424850. DOI: 10.3389/fped.2023.1239423. View

Das M, Arora N, Mathai J, Sam C, G R, R K . Profile and Epidemiology of Intussusception in Children Under-Two Years of Age: A Prospective Surveillance. Indian J Pediatr. 2021; 88(12):1187-1194. DOI: 10.1007/s12098-021-03776-8. View

Chen B, Cao J, Yan C, Zheng C, Chen J, Guo C . A promising new predictive factor for detecting bowel resection in childhood intussusception: the lymphocyte-C-reactive protein ratio. BMC Pediatr. 2021; 21(1):577. PMC: 8675458. DOI: 10.1186/s12887-021-03068-2. View

Delgado-Miguel C, Garcia A, Delgado B, Munoz-Serrano A, Miguel-Ferrero M, Camps J . Neutrophil-to-Lymphocyte Ratio as a Predictor of the Need for Surgical Treatment in Children's Intussusception. Eur J Pediatr Surg. 2022; 33(5):422-427. DOI: 10.1055/a-1913-4280. View

Lu H, Ding Y, Goyal H, Xu H . Association Between Rotavirus Vaccination and Risk of Intussusception Among Neonates and Infants: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019; 2(10):e1912458. PMC: 6784808. DOI: 10.1001/jamanetworkopen.2019.12458. View

Chen X, Chen Q, Wang X, Gao Z . Clinical characteristics of recurrent intussusception: A single-center retrospective study. J Pediatr Surg. 2021; 56(10):1831-1834. DOI: 10.1016/j.jpedsurg.2021.03.051. View

10.

Okuyan O, Elgormus Y, Sayili U, Dumur S, Isik O, Uzun H . The Effect of Virus-Specific Vaccination on Laboratory Infection Markers of Children with Acute Rotavirus-Associated Acute Gastroenteritis. Vaccines (Basel). 2023; 11(3). PMC: 10051053. DOI: 10.3390/vaccines11030580. View

11.

Jehangir S, John J, Rajkumar S, Mani B, Srinivasan R, Kang G . Intussusception in southern India: comparison of retrospective analysis and active surveillance. Vaccine. 2014; 32 Suppl 1:A99-103. DOI: 10.1016/j.vaccine.2014.03.028. View

12.

Sun Z, Song G, Lian D, Zhang Q, Dong L . Process Management of Intussusception in Children: A Retrospective Analysis in China. Pediatr Emerg Care. 2022; 38(7):321-325. PMC: 9245550. DOI: 10.1097/PEC.0000000000002700. View

13.

Wang J, Zhang H, Zhang H, Fang H . Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs. Hum Vaccin Immunother. 2022; 18(7):2090162. PMC: 10019831. DOI: 10.1080/21645515.2022.2090162. View

14.

Kim P, Hwang J, Yoon H, Lee J, Jung A, Lee J . Predictors of failed enema reduction in children with intussusception: a systematic review and meta-analysis. Eur Radiol. 2021; 31(11):8081-8097. DOI: 10.1007/s00330-021-07935-5. View

15.

Zhang T, Cui L, Geng X, Yu X, Zhang J . Epidemiology study of pediatric primary intussusception aged ≤24 months in pre-rotavirus vaccine era of Jinan, China. Vaccine. 2019; 37(11):1436-1442. DOI: 10.1016/j.vaccine.2019.01.060. View

16.

Tate J, Mwenda J, Keita A, Tapsoba T, Ngendahayo E, Kouame B . Evaluation of Intussusception Following Pentavalent Rotavirus Vaccine (RotaTeq) Administration in 5 African Countries. Clin Infect Dis. 2023; 78(1):210-216. PMC: 11497219. DOI: 10.1093/cid/ciad492. View

17.

Cho H, Hwang S, Nam H, Han K, Kim B, Kong I . Incidence of intussusception before and after the introduction of rotavirus vaccine in Korea. PLoS One. 2020; 15(8):e0238185. PMC: 7454960. DOI: 10.1371/journal.pone.0238185. View

18.

Guo W, Geng J, Zhan Y, Tan Y, Hu Z, Pan P . Forecasting and predicting intussusception in children younger than 48 months in Suzhou using a seasonal autoregressive integrated moving average model. BMJ Open. 2019; 9(1):e024712. PMC: 6340449. DOI: 10.1136/bmjopen-2018-024712. View

19.

Tseng W, Chao H, Chen C, Lai M, Chang Y . Adenovirus infection is a risk factor for recurrent intussusception in pediatric patients. Pediatr Neonatol. 2023; 64(4):428-434. DOI: 10.1016/j.pedneo.2022.03.024. View

20.

Cohen R, Martinon-Torres F, Posiuniene I, Benninghoff B, Oh K, Poelaert D . The Value of Rotavirus Vaccination in Europe: A Call for Action. Infect Dis Ther. 2022; 12(1):9-29. PMC: 9647247. DOI: 10.1007/s40121-022-00697-7. View